share_log

Monte Rosa Therapeutics Says Initial Clinical Data From Phase 1 SAD/MAD Study of VAV1-directed Molecular Glue Degrader (MGD) MRT-6160 Expected In Q1 2025

Monte Rosa Therapeutics Says Initial Clinical Data From Phase 1 SAD/MAD Study of VAV1-directed Molecular Glue Degrader (MGD) MRT-6160 Expected In Q1 2025

Monte Rosa Therapeutics表示,針對VAV1定向分子膠水降解劑(MGD)MRt-6160的第一階段SAD/MAD研究的初步臨牀數據預計在2025年第一季度發佈。
Benzinga ·  01/10 20:16

Monte Rosa Therapeutics Says Initial Clinical Data From Phase 1 SAD/MAD Study of VAV1-directed Molecular Glue Degrader (MGD) MRT-6160 Expected In Q1 2025

Monte Rosa Therapeutics表示,針對VAV1導向的分子膠水降解劑(MGD)MRt-6160的1期SAD/MAD研究的初步臨牀數據預計在2025年第一季度公佈

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論